A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Dec 2018
At a glance
- Drugs KDT 3594 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kissei Pharmaceutical
- 05 Dec 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2017 New trial record